KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Receivables (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Change in Receivables for 7 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 99.67% to $30.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.0 million through Dec 2025, up 3684.01% year-over-year, with the annual reading at $88.0 million for FY2025, 3684.01% up from the prior year.
  • Change in Receivables hit $30.2 million in Q4 2025 for GoodRx Holdings, up from $14.7 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $30.2 million in Q4 2025 to a low of -$31.0 million in Q3 2024.
  • Historically, Change in Receivables has averaged $8.0 million across 5 years, with a median of $7.1 million in 2021.
  • Biggest five-year swings in Change in Receivables: surged 4084.36% in 2021 and later plummeted 1287.59% in 2024.
  • Year by year, Change in Receivables stood at $19.6 million in 2021, then tumbled by 119.14% to -$3.7 million in 2022, then soared by 699.79% to $22.5 million in 2023, then crashed by 32.64% to $15.1 million in 2024, then skyrocketed by 99.67% to $30.2 million in 2025.
  • Business Quant data shows Change in Receivables for GDRX at $30.2 million in Q4 2025, $14.7 million in Q3 2025, and $28.9 million in Q2 2025.